|
DECREASED LITHIUM RENAL CLEARANCE RESULTING IN INCREASED LITHIUM PLASMA LEVELS ; POTENTIAL FOR LITHIUM TOXICITY
|
DECREASED LITHIUM RENAL CLEARANCE RESULTING IN INCREASED LITHIUM PLASMA LEVELS ; POTENTIAL FOR LITHIUM TOXICITY
|
DIURETICS REDUCE LITHIUMS RENAL CLEARANCE AND ADD A HIGH RISK OF LITHIUM TOXICITY
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
LITHIUM MAY CAUSE IRREVERSIBLE BRAIN DAMAGE WHEN CONCURRENTLY GIVEN
|
MAY EITHER POTENTIATE OR WEAKEN THE BLOOD GLUCOSE LOWERING EFFECT OF INSULIN
|
MAY EITHER POTENTIATE OR WEAKEN THE BLOOD GLUCOSE LOWERING EFFECT OF INSULIN
|
MAY EITHER POTENTIATE OR WEAKEN THE BLOOD GLUCOSE LOWERING EFFECT OF INSULIN
|
MAY EITHER POTENTIATE OR WEAKEN THE BLOOD GLUCOSE LOWERING EFFECT OF INSULIN
|
MAY EITHER POTENTIATE OR WEAKEN THE BLOOD GLUCOSE LOWERING EFFECT OF INSULIN
|
MAY EITHER POTENTIATE OR WEAKEN THE BLOOD GLUCOSE LOWERING EFFECT OF INSULIN
|
DIURETICS REDUCE THE RENAL CLEARANCE OF LITHIUM AND ADD A HIGH RISK OF LITHIUM TOXICITY
|
DIURETICS REDUCE THE RENAL CLEARANCE OF LITHIUM AND ADD A HIGH RISK OF LITHIUM TOXICITY
|
LITHIUM PLASMA LEVELS ARE RAISED BY THE DRUG
|
DIURETICS REDUCE THE RENAL CLEARANCE OF LITHIUM AND ADD A HIGH RISK OF LITHIUM TOXICITY
|
DECREASED LITHIUM RENAL CLEARANCE RESULTING IN INCREASED LITHIUM PLASMA LEVELS ; POTENTIAL FOR LITHIUM TOXICITY
|
MAY EITHER POTENTIATE OR WEAKEN THE BLOOD GLUCOSE LOWERING EFFECT OF INSULIN
|
LITHIUM ENHANCES HYPOTHYROID EFFECT OF COLLOIDAL IODINE
|
LITHIUM ENHANCES HYPOTHYROID EFFECT OF COLLOIDAL IODINE
|
MAY EITHER POTENTIATE OR WEAKEN THE BLOOD GLUCOSE LOWERING EFFECT OF INSULIN
|
DECREASED LITHIUM RENAL CLEARANCE RESULTING IN INCREASED LITHIUM PLASMA LEVELS ; POTENTIAL FOR LITHIUM TOXICITY
|
DECREASED LITHIUM RENAL CLEARANCE RESULTING IN INCREASED LITHIUM PLASMA LEVELS ; POTENTIAL FOR LITHIUM TOXICITY
|
POTENTIAL FOR INCREASED SERUM LITHIUM LEVELS AND TOXICITY
|
MAY EITHER POTENTIATE OR WEAKEN THE BLOOD GLUCOSE LOWERING EFFECT OF INSULIN
|
LITHIUM INHIBITS THE ANORECTIC AND STIMULATORY EFFECTS OF AMPHETAMINE
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
NEUROMUSCULAR BLOCKING EFFECT IS ENHANCED
|
NEUROMUSCULAR BLOCKING EFFECT IS ENHANCED
|
LITHIUM INHIBITS THE ANORECTIC AND STIMULATORY EFFECTS OF AMPHETAMINE
|
LITHIUM INHIBITS THE ANORECTIC AND STIMULATORY EFFECTS OF AMPHETAMINE
|
LITHIUM INHIBITS THE ANORECTIC AND STIMULATORY EFFECTS OF AMPHETAMINE
|
DECREASED LITHIUM RENAL CLEARANCE RESULTING IN INCREASED LITHIUM PLASMA LEVELS ; POTENTIAL FOR LITHIUM TOXICITY
|
DIURETICS REDUCE LITHIUMS RENAL CLEARANCE AND ADD A HIGH RISK OF LITHIUM TOXICITY
|
MAY EITHER POTENTIATE OR WEAKEN THE BLOOD GLUCOSE LOWERING EFFECT OF INSULIN
|
MAY EITHER POTENTIATE OR WEAKEN THE BLOOD GLUCOSE LOWERING EFFECT OF INSULIN
|
MAY EITHER POTENTIATE OR WEAKEN THE BLOOD GLUCOSE LOWERING EFFECT OF INSULIN
|
DIURETICS REDUCE LITHIUMS RENAL CLEARANCE AND ADD A HIGH RISK OF LITHIUM TOXICITY
|
POTENTIAL FOR REVERSIBLE LITHIUM TOXICITY ; FREQUENT MONITORING OF LITHIUM LEVELS IN RECOMMENDED
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED STEADY-STATE LITHIUM PLASMA LEVELS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
DIURETICS REDUCE THE RENAL CLEARANCE OF LITHIUM AND ADD A HIGH RISK OF LITHIUM TOXICITY
|
DIURETICS REDUCE THE RENAL CLEARANCE OF LITHIUM AND ADD A HIGH RISK OF LITHIUM TOXICITY
|
SECNIDAZOLE IMPAIRES METABOLISM OR INCREASE EXCRETION OF THE DRUG
|
DECREASED LITHIUM RENAL CLEARANCE RESULTING IN INCREASED LITHIUM PLASMA LEVELS ; POTENTIAL FOR LITHIUM TOXICITY
|
LITHIUM PLASMA LEVELS ARE RAISED BY THE DRUG
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
POTENTIAL FOR REVERSIBLE LITHIUM TOXICITY ; FREQUENT MONITORING OF LITHIUM LEVELS IN RECOMMENDED
|
DECREASED LITHIUM RENAL CLEARANCE RESULTING IN INCREASED LITHIUM PLASMA LEVELS ; POTENTIAL FOR LITHIUM TOXICITY
|
DECREASED LITHIUM RENAL CLEARANCE RESULTING IN INCREASED LITHIUM PLASMA LEVELS ; POTENTIAL FOR LITHIUM TOXICITY
|
MAY EITHER POTENTIATE OR WEAKEN THE BLOOD GLUCOSE LOWERING EFFECT OF INSULIN
|
MAY EITHER POTENTIATE OR WEAKEN THE BLOOD GLUCOSE LOWERING EFFECT OF INSULIN
|
MAY EITHER POTENTIATE OR WEAKEN THE BLOOD GLUCOSE LOWERING EFFECT OF INSULIN
|
MAY EITHER POTENTIATE OR WEAKEN THE BLOOD GLUCOSE LOWERING EFFECT OF INSULIN
|
LITHIUM ENHANCES HYPOTHYROID EFFECT OF COLLOIDAL IODINE
|
DECREASED LITHIUM RENAL CLEARANCE RESULTING IN INCREASED LITHIUM PLASMA LEVELS ; POTENTIAL FOR LITHIUM TOXICITY
|
MAY EITHER POTENTIATE OR WEAKEN THE BLOOD GLUCOSE LOWERING EFFECT OF INSULIN
|
POTENTIAL FOR REVERSIBLE LITHIUM TOXICITY ; FREQUENT MONITORING OF LITHIUM LEVELS IN RECOMMENDED
|
POTENTIAL FOR REVERSIBLE LITHIUM TOXICITY ; FREQUENT MONITORING OF LITHIUM LEVELS IN RECOMMENDED
|
DECREASED LITHIUM RENAL CLEARANCE RESULTING IN INCREASED LITHIUM PLASMA LEVELS ; POTENTIAL FOR LITHIUM TOXICITY
|
LITHIUM PLASMA LEVELS ARE RAISED BY THE DRUG
|
MAY EITHER POTENTIATE OR WEAKEN THE BLOOD GLUCOSE LOWERING EFFECT OF INSULIN
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
MAY EITHER POTENTIATE OR WEAKEN THE BLOOD GLUCOSE LOWERING EFFECT OF INSULIN
|
MAY EITHER POTENTIATE OR WEAKEN THE BLOOD GLUCOSE LOWERING EFFECT OF INSULIN
|
MAY EITHER POTENTIATE OR WEAKEN THE BLOOD GLUCOSE LOWERING EFFECT OF INSULIN
|
MAY EITHER POTENTIATE OR WEAKEN THE BLOOD GLUCOSE LOWERING EFFECT OF INSULIN
|
MAY EITHER POTENTIATE OR WEAKEN THE BLOOD GLUCOSE LOWERING EFFECT OF INSULIN
|
LITHIUM ENHANCES HYPOTHYROID EFFECT OF COLLOIDAL IODINE
|
LITHIUM PLASMA LEVELS ARE RAISED BY THE DRUG
|
DESMOPRESSIN ANTIDIURETIC EFFECT IS REDUCED BY THE DRUG
|
DECREASED LITHIUM RENAL CLEARANCE RESULTING IN INCREASED LITHIUM PLASMA LEVELS ; POTENTIAL FOR LITHIUM TOXICITY
|
DECREASED LITHIUM RENAL CLEARANCE RESULTING IN INCREASED LITHIUM PLASMA LEVELS ; POTENTIAL FOR LITHIUM TOXICITY
|
POTENTIAL FOR INCREASED SERUM LITHIUM LEVELS AND TOXICITY
|
POTENTIAL FOR REVERSIBLE LITHIUM TOXICITY ; FREQUENT MONITORING OF LITHIUM LEVELS IN RECOMMENDED
|
POTENTIAL FOR INCREASED SERUM LITHIUM LEVELS AND TOXICITY
|
DECREASED LITHIUM RENAL CLEARANCE RESULTING IN INCREASED LITHIUM PLASMA LEVELS ; POTENTIAL FOR LITHIUM TOXICITY
|
SECNIDAZOLE IMPAIRES METABOLISM OR INCREASE EXCRETION OF THE DRUG
|
SECNIDAZOLE IMPAIRES METABOLISM OR INCREASE EXCRETION OF THE DRUG
|
LITHIUM ENHANCES HYPOTHYROID EFFECT OF COLLOIDAL IODINE
|
LITHIUM PLASMA LEVELS ARE RAISED BY THE DRUG
|
NEUROMUSCULAR BLOCKING EFFECT IS ENHANCED
|
SUMATRIPTAN WHEN CONCURRENTLY GIVEN IN A PATIENT HAVE INCREASED CHANCES OF DEVELOPING SIDE EFFECTS
|
DECREASED LITHIUM RENAL CLEARANCE RESULTING IN INCREASED LITHIUM PLASMA LEVELS ; POTENTIAL FOR LITHIUM TOXICITY
|
TERLIPRESSIN ANTIDIURETIC EFFECT IS DECREASED BY THE DRUG
|
LITHIUM PLASMA LEVELS ARE RAISED BY THE DRUG
|
SECNIDAZOLE IMPAIRES METABOLISM OR INCREASE EXCRETION OF THE DRUG
|
DECREASED LITHIUM RENAL CLEARANCE RESULTING IN INCREASED LITHIUM PLASMA LEVELS ; POTENTIAL FOR LITHIUM TOXICITY
|
LITHIUM PLASMA LEVELS ARE RAISED BY THE DRUG
|
LITHIUM PLASMA LEVELS ARE RAISED BY THE DRUG
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
VERAPAMIL LOWERS SERUM LITHIUM LEVELS IN A STABLE LITHIUM LEVEL PATIENT BUT SENSTIVITY TO THE EFFECTS OF LITHIUM IS INCREASED
|
DIURETICS REDUCE THE RENAL CLEARANCE OF LITHIUM AND ADD A HIGH RISK OF LITHIUM TOXICITY
|
MAY EITHER POTENTIATE OR WEAKEN THE BLOOD GLUCOSE LOWERING EFFECT OF INSULIN
|
POTENTIAL FOR INCREASED SERUM LITHIUM LEVELS AND TOXICITY
|
ACETAZOLAMIDE INCREASE THE EXCRETION OF LITHIUM CARBONATE UNLIKE THIAZIDE DIURETICS
|
LITHIUM PLASMA LEVELS ARE RAISED BY THE DRUG
|